Webinars and Sponsored Roundtables — Register Now

Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.

Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications. 

Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.

Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Hematology Analyzers, 2024

[one_third]

[/one_third]

[two_third_last]

[/two_third_last]

[wpdatatable id=106]

[one_third]

[/one_third]

[two_third_last]

Can labs bridge the hematology data disconnect?

October 2024—Do clinicians understand how the technology in hematology has evolved and how laboratory data can help guide their decisions? It’s a question roundtable participants took on when they met online Aug. 29 with CAP TODAY publisher Bob McGonnagle. “There’s a disconnect with our clinical colleagues,” said Olga Pozdnyakova, MD, PhD, of the Hospital of the University of Pennsylvania. She and others spoke about solutions, instruments, AI, and reference ranges—in addition to the staffing shortage. “It is first and foremost in our minds,” Maria (Ria) Vergara-Lluri, MD, of Keck School of Medicine of USC, said of the ongoing shortage.

Following their conversation below is an all-new CAP TODAY guide to hematology analyzers (pages 41–51). The questions we asked vendors about their instruments were updated and revised for the first time, providing new insight into the instruments on the market.

A few issues from our discussion in last year’s roundtable on hematology analyzers carry over to today’s conversation: the efforts to cut back on the number of manual differentials we’re asking to have done in labs; the continuing work around bands versus neutrophils; the remote viewing of cells, à la surgical pathology, when we want an automated look at blood cells; and artificial intelligence in the world of hematology. Fernando Chaves, is there something new here? Where do you place us in the state of hematology today?

Fernando Chaves, MD, director, medical and scientific affairs, specialty lab solutions, Siemens Healthineers: Our main focus continues to be on digitalization and digital integration to improve patient care and workflow. For manual reviews, it’s not a question of how many slides are needed but how much labor and turnaround time are required to review a slide. That’s why we focus on the importance of digital morphology, the ability to use digital hematology, which gives a full-field view on a computer screen and the same experience as you have on a microscope. You see not only random selected cells but also a view of the entire slide. You can see the context of each cell, navigate through the slide on the computer screen, and do it remotely. It saves time and shortens turnaround time.

Continue reading …
[/two_third_last]